Chinese biotech firm Vcanbio Cell & Gene Engineering Corporation has led a series B round in Genetron Health, a Beijing-based cancer genomics solutions start-up.
New Horizon Capital and existing investors Shenzhen Share Capital Partners, Yueyin Venture and others also participated in the round, which is reportedly worth hundreds of millions RMB.
The company says it will use the proceeds on marketing and product expansion, as well as building up its big data capabilities.
Genetron Health focuses on providing precision healthcare in cancer detection, prevention, and treatment based on genetic testing.
It currently has research centers in Beijing and North Carolina, with clinical labs in Beijing, Shanghai and Hangzhou.